Abdelsattar M E Omar

List of Publications by Citations

38	287	11	15
papers	citations	h-index	g-index
43	414	4.8	3.45
ext. papers	ext. citations	avg, IF	L-index

#	Paper	IF	Citations
38	Design, synthesis, molecular docking of new lipophilic acetamide derivatives affording potential anticancer and antimicrobial agents. *Bioorganic Chemistry*, **2018**, 76, 332-342	5.1	28
37	Design, synthesis and in vivo anti-inflammatory activities of 2,4-diaryl-5-4H-imidazolone derivatives. *Molecules*, **2012**, 17, 12262-75	4.8	27
36	Design, synthesis, and biological evaluation studies of novel quinazolinone derivatives as anticonvulsant agents. *Medicinal Chemistry Research*, **2013**, 22, 5823-5831	2.2	23
35	Novel scaffold hopping of potent benzothiazole and isatin analogues linked to 1,2,3-triazole fragment that mimic quinazoline epidermal growth factor receptor inhibitors: Synthesis, antitumor and mechanistic analyses. *Bioorganic Chemistry*, **2020**, 103, 104133	5.1	20
34	Crystal structure of carbonmonoxy sickle hemoglobin in R-state conformation. *Journal of Structural Biology*, **2016**, 194, 446-50	3.4	19
33	Molecular Mimics of Classic P-Glycoprotein Inhibitors as Multidrug Resistance Suppressors and Their Synergistic Effect on Paclitaxel. *PLoS ONE*, **2017**, 12, e0168938	3.7	18
32	The rational design, synthesis, and antimicrobial investigation of 2-Amino-4-Methylthiazole analogues inhibitors of GlcN-6-P synthase. *Bioorganic Chemistry*, **2020**, 99, 103781	5.1	17
31	Synthesis and screening of some new fluorinated quinazolinone‐sulphonamide hybrids as anticancer agents. *Journal of Taibah University Medical Sciences*, **2015**, 10, 333-339	1.7	16
30	Novel molecular discovery of promising amidine-based thiazole analogues as potent dual Matrix Metalloproteinase-2 and 9 inhibitors: Anticancer activity data with prominent cell cycle arrest and DNA fragmentation analysis effects. *Bioorganic Chemistry*, **2020**, 101, 103992	5.1	15
29	Synthesis, Modelling, and Anticonvulsant Studies of New Quinazolines Showing Three Highly Active Compounds with Low Toxicity and High Affinity to the GABA-A Receptor. *Molecules*, **2017**, 22,	4.8	14
28	Identification of a novel class of covalent modifiers of hemoglobin as potential antisickling agents. *Organic and Biomolecular Chemistry*, **2015**, 13, 6353-70	3.9	12
27	Antimicrobial screening and pharmacokinetic profiling of novel phenyl-[1,2,4]triazolo[4,3-a]quinoxaline analogues targeting DHFR and E. coli DNA gyrase B. *Bioorganic Chemistry*, **2020**, 96, 103656	5.1	9
26	Design, Synthesis, and Investigation of Novel Nitric Oxide (NO)-Releasing Prodrugs as Drug Candidates for the Treatment of Ischemic Disorders: Insights into NO-Releasing Prodrug Biotransformation and Hemoglobin-NO Biochemistry. *Biochemistry*, **2015**, 54, 7178-92	3.2	7
25	1-Imidazole-2,5-Dicarboxamides as NS4A Peptidomimetics: Identification of a New Approach to Inhibit HCV-NS3 Protease. *Biomolecules*, **2020**, 10,	5.9	5
24	Targeted potent antimicrobial benzochromene-based analogues: Synthesis, computational studies, and inhibitory effect against 14‐Demethylase and DNA Gyrase. *Bioorganic Chemistry*, **2020**, 105, 104387	5.1	5
23	Zein-alpha lipoic acid-loaded nanoparticles to enhance the oral bioavailability of dapoxetine: optimization and clinical pharmacokinetic evaluation. *International Journal of Nanomedicine*, **2019**, 14, 7461-7473	7.3	4
22	VZHE-039, a novel antisickling agent that prevents erythrocyte sickling under both hypoxic and anoxic conditions. *Scientific Reports*, **2020**, 10, 20277	4.9	4

21	Potent Quinoline-Containing Combretastatin A-4 Analogues: Design, Synthesis, Antiproliferative, and Anti-Tubulin Activity. *Pharmaceuticals*, **2020**, 13,	5.2	4
20	Discovery of novel quinoline-based analogues of combretastatin A-4 as tubulin polymerisation inhibitors with apoptosis inducing activity and potent anticancer effect. *Journal of Enzyme Inhibition and Medicinal Chemistry*, **2021**, 36, 802-818	5.6	4
19	Design, Synthesis and Antiproliferative Activities of Oxidative Stress Inducers Based on 2-Styryl-3,5-dihydro-4H-imidazol-4-one Scaffold. *Chemical and Pharmaceutical Bulletin*, **2018**, 66, 967-975	1.9	3
18	Chaetomugilins and Chaetoviridins-Promising Natural Metabolites: Structures, Separation, Characterization, Biosynthesis, Bioactivities, Molecular Docking, and Molecular Dynamics.. *Journal of Fungi (Basel, Switzerland)*, **2022**, 8,	5.6	3
17	Discovery and SAR of Novel Disubstituted Quinazolines as Dual PI3Kalpha/mTOR Inhibitors Targeting Breast Cancer. *ACS Medicinal Chemistry Letters*, **2020**, 11, 2156-2164	4.3	3
16	An Investigation of Structure-Activity Relationships of Azolylacryloyl Derivatives Yielded Potent and Long-Acting Hemoglobin Modulators for Reversing Erythrocyte Sickling. *Biomolecules*, **2020**, 10,	5.9	3
15	Phytoconstituents, Anti-Infective Activity of Lam., and Evaluation of its SARS-CoV-2 Inhibitory Potential. *Frontiers in Pharmacology*, **2021**, 12, 619373	5.6	3
14	Inborn errors in the vitamin B6 salvage enzymes associated with neonatal epileptic encephalopathy and other pathologies. *Biochimie*, **2021**, 183, 18-29	4.6	3
13	Thiophenes-Naturally Occurring Plant Metabolites: Biological Activities and In Silico Evaluation of Their Potential as Cathepsin D Inhibitors.. *Plants*, **2022**, 11,	4.5	3
12	Introducing of potent cytotoxic novel 2-(aroylamino)cinnamamide derivatives against colon cancer mediated by dual apoptotic signal activation and oxidative stress. *Bioorganic Chemistry*, **2020**, 101, 103953	5.1	2
11	Structural modification of azolylacryloyl derivatives yields a novel class of covalent modifiers of hemoglobin as potential antisickling agents. *MedChemComm*, **2019**, 10, 1900-1906	5	2
10	Aryloxyalkanoic Acids as Non-Covalent Modifiers of the Allosteric Properties of Hemoglobin. *Molecules*, **2016**, 21,	4.8	2
9	Synthetic bulky NS4A peptide variants bind to and inhibit HCV NS3 protease. *Journal of Advanced Research*, **2020**, 24, 251-259	13	2
8	Improving the Solubility and Oral Bioavailability of a Novel Aromatic Aldehyde Antisickling Agent (PP10) for the Treatment of Sickle Cell Disease. *Pharmaceutics*, **2021**, 13,	6.4	2
7	Exploring the Activity of Fungal Phenalenone Derivatives as Potential CK2 Inhibitors Using Computational Methods. *Journal of Fungi (Basel, Switzerland)*, **2022**, 8, 443	5.6	2
6	A single-step synthesis of 1,3,4,6-tetraaryl-5-aryliminopiperazin-2-one. *Journal of Heterocyclic Chemistry*, **2021**, 58, 442-449	1.9	1
5	Molecular insight into 2-phosphoglycolate activation of the phosphatase activity of bisphosphoglycerate mutase.. *Acta Crystallographica Section D: Structural Biology*, **2022**, 78, 472-482	5.5	1
4	Modulating hemoglobin allostery for treatment of sickle cell disease: current progress and intellectual property. *Expert Opinion on Therapeutic Patents*, **2021**, 1-16	6.8	0

3	Insights on Cancer Cell Inhibition, Subcellular Activities, and Kinase Profile of Phenylacetamides Pending 1-Imidazol-5-One Variants.. *Frontiers in Pharmacology*, **2021**, 12, 794325	5.6
2	Reexamining Povarov Reaction: Scope and Limitation in the Generation of HCV-NS4A Peptidomimetics. *Heteroatom Chemistry*, **2022**, 2022, 1-12	1.2
1	Pairing 3D-Printing with Nanotechnology to Manage Metabolic Syndrome.. *International Journal of Nanomedicine*, **2022**, 17, 1783-1801	7.3